menu search

Theseus pharmaceuticals to present preclinical data characterizing next-generation epidermal growth factor receptor (egfr) inhibitors at the 2022 american association for cancer research (aacr) annual

CAMBRIDGE, Mass., March 8, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceut...

March 8, 2022, 5:01 pm

Theseus pharmaceuticals to present preclinical data characterizing next-generation epidermal growth factor receptor (egfr) inhibitors at the 2022 american association for cancer research (aacr) annual

CAMBRIDGE, Mass., March 8, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceut...

March 8, 2022, 5:01 pm

Theseus pharmaceuticals to present preclinical data characterizing next-generation epidermal growth factor receptor (egfr) inhibitors at the 2022 american association for cancer research (aacr) annual

CAMBRIDGE, Mass., March 8, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceut...

March 8, 2022, 5:01 pm

Hookipa to present new preclinical, translational, and clinical biomarker data at aacr further supporting the potential of arenaviral platform in oncology

NEW YORK and VIENNA, Austria, March 08, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of ...

March 8, 2022, 4:51 pm

Sqz biotechnologies to present new enhanced apc platform preclinical findings and envoy-001 phase 1/2 clinical trial in progress poster at the american association for cancer research 2022 annual meet

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple the...

March 8, 2022, 4:45 pm

Sqz biotechnologies to present new enhanced apc platform preclinical findings and envoy-001 phase 1/2 clinical trial in progress poster at the american association for cancer research 2022 annual meet

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple the...

March 8, 2022, 4:45 pm

Xencor to present preclinical data from xmab® cytokine programs at the american association for cancer research (aacr) annual meeting 2022

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytoki...

March 8, 2022, 4:31 pm

Ikena oncology to present preclinical findings on ik-930, a novel tead inhibitor at the 2022 american association for cancer research (aacr) annual meeting

BOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-direct...

March 7, 2022, 4:30 pm

Lava therapeutics shares interim lava-051 data from early-stage cancer trial

LAVA Therapeutics NV (NASDAQ: LVTX) announced initial data from its first clinical study with LAVA-051.  The presentation will include data from t...

March 7, 2022, 12:19 pm

Lava therapeutics shares interim lava-051 data from early-stage cancer trial

LAVA Therapeutics NV (NASDAQ: LVTX) announced initial data from its first clinical study with LAVA-051.  The presentation will include data from t...

March 7, 2022, 12:19 pm

Lava therapeutics shares interim lava-051 data from early-stage cancer trial

LAVA Therapeutics NV (NASDAQ: LVTX) announced initial data from its first clinical study with LAVA-051.  The presentation will include data from t...

March 7, 2022, 12:19 pm

Vyne therapeutics' bet inhibitor shows encouraging preclinical action in skin disorder

VYNE Therapeutics Inc (NASDAQ: VYNE) has announced preclinical data in an ex vivo skin model of vi...

March 7, 2022, 12:06 pm

Vyne therapeutics' bet inhibitor shows encouraging preclinical action in skin disorder

VYNE Therapeutics Inc (NASDAQ: VYNE) has announced preclinical data in an ex vivo skin model of vi...

March 7, 2022, 12:06 pm

Vyne therapeutics' bet inhibitor shows encouraging preclinical action in skin disorder

VYNE Therapeutics Inc (NASDAQ: VYNE) has announced preclinical data in an ex vivo skin model of vi...

March 7, 2022, 12:06 pm

Annexon biosciences to present preclinical data supporting complement inhibitor programs for the treatment of guillain-barré syndrome and huntington's disease at aan 2022

BRISBANE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developi...

March 3, 2022, 4:01 pm

Annexon biosciences to present preclinical data supporting complement inhibitor programs for the treatment of guillain-barré syndrome and huntington's disease at aan 2022

BRISBANE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developi...

March 3, 2022, 4:01 pm

Annexon biosciences to present preclinical data supporting complement inhibitor programs for the treatment of guillain-barré syndrome and huntington's disease at aan 2022

BRISBANE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developi...

March 3, 2022, 4:01 pm

Ac immune to present at the ad/pd™ 2022 new clinical and preclinical data for alpha-synuclein, abeta and tdp-43 programs

Five presentations at the International Conference on Alzheimer's & Parkinson's Diseases (AD/PD TM )...

February 28, 2022, 7:30 am

Ac immune to present at the ad/pd™ 2022 new clinical and preclinical data for alpha-synuclein, abeta and tdp-43 programs

Five presentations at the International Conference on Alzheimer's & Parkinson's Diseases (AD/PD TM )...

February 28, 2022, 7:30 am

Ac immune to present at the ad/pd™ 2022 new clinical and preclinical data for alpha-synuclein, abeta and tdp-43 programs

Five presentations at the International Conference on Alzheimer's & Parkinson's Diseases (AD/PD TM )...

February 28, 2022, 7:30 am


Search within

Pages Search Results: